BioSpace News Archive

Coya Therapeutics, Inc. announces the expansion of its research collaboration with the Houston Methodist Research Institute (“HMRI”) through a sponsored research agreement (SRA) covering multiple initiatives.

Femasys, Inc., a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces it has received its European Union Medical Device Regulation certificate and CE Mark certification for four of its products.

Nexalin Technology, Inc. announced that the United States Patent and Trademark Office has awarded U.S. Patent No 12,011,591 relating to the Company’s non-invasive Deep Intracranial Frequency Stimulation medical device for the treatment of Alzheimer’s and other dementia-related brain diseases.

Bristol Myers Squibb (NYSE: BMY) will announce results for the second quarter of 2024 on Friday, July 26, 2024. Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning at 8:00 a.m. ET on the same date.

Accuray Incorporated announced an agreement with TrueNorth Medical Physics LLC to provide radiation oncology departments with third-party support designed to enhance their department’s capabilities.

Crescita Therapeutics Inc. today announced that it has agreed to acquire all of the non-real estate business assets of Occy Laboratory Inc., (“Occy”), a Laval-based manufacturer and distributor of high-quality dermocosmetic products (the “Transaction”).

Spinogenix, Inc. today announced that the initiation of Spinogenix’s Phase 2 trial to evaluate SPG302 for the treatment of adult participants with mild-to-moderate Alzheimer’s disease (AD) was approved in Australia.

Tempest Therapeutics, Inc. announced new positive data from the ongoing global randomized Phase 1b/2 clinical study in which amezalpat2, Tempest’s PPAR⍺ antagonist, delivered a six-month improvement in median overall survival advantage when combined with atezolizumab and bevacizumab in a comparison to atezolizumab and bevacizumab alone in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma.

Critical Path Institute and Centogene N.V. are pleased to announce the signing of a Memorandum of Understanding to advance drug development for lysosomal diseases and improve the quality of life for those impacted by these conditions.

The Board of Directors of Regel Therapeutics announced that Stephen J. Farr , PhD, begins today as Chief Executive Officer (CEO).